The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Remaining questions on PSMA PET imaging in prostate cancer
Anis Hamid, MBBS, Dana-Farber Cancer Institute, Boston, MA, discusses remaining questions on PSMA PET imaging in prostate cancer, predominantly on establishing the role and combinations for lutetium, PSMA and other ligand treatments. PSMA PET imaging has an established role for understanding the biology of prostate cancer. Defining who is suitable for lutetium PSMA-based treatments is a key area of focus. Automated approaches for defining thresholds in terms of patient benefit from radioligand therapy will become increasingly utilized. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
